Contributions
Abstract: PB1718
Type: Publication Only
Session title: Myeloproliferative neoplasms - Clinical
Background
Myelofibrosis is an uncommon myeloproliferative neoplasm, characterized by stem cell-derived clonal proliferation that is often accompanied by JAK2, CALR, or MPL mutations. It presents with marrow fibrosis, variable degree of splenomegaly, cytopaenias and constitutional symptoms, that significantly impact on quality of life and survival.
Aims
Ruxolitinib is a JAK 1/2 inhibitor that can decrease spleen size, relieve constitutional symptoms, reduce transfusion requirement and prolongs survival in some patients. Uncommon adverse reaction of Ruxolitinib includes reactivation of tuberculosis infection.
Methods
We are describing 4 patients of myelofibrosis who have had reactivation of tuberculosis, whilst on Ruxolitinib. Data was collected retrospectively. Patients were followed up actively during antituberculous treatment
Results
Age (yr) sex Diagnosis JAK2 CALR Ruxolitinib initi TB reactivation Site of reactivation ATT outcome
53 F SMF/PV + - Dec, 2013 15 months Abdominal 6 month Alive
33 F PMF + - Feb, 2016 14 months Pulmonary 6 months Alive 40 M PMF - + Apr, 2017 4 months Lymphnode 6 months Alive 54 M PMF + - Mar, 2017 11 months Pulmonary 6 months Alive
Conclusion
Tuberculosis infection was observed in 4 patients who were being treated with Ruxolitinib. This case series highlights the importance of screening for latent tuberculosis in patients from highly endemic areas before commencing on Ruxolitinib.
Keyword(s):
Abstract: PB1718
Type: Publication Only
Session title: Myeloproliferative neoplasms - Clinical
Background
Myelofibrosis is an uncommon myeloproliferative neoplasm, characterized by stem cell-derived clonal proliferation that is often accompanied by JAK2, CALR, or MPL mutations. It presents with marrow fibrosis, variable degree of splenomegaly, cytopaenias and constitutional symptoms, that significantly impact on quality of life and survival.
Aims
Ruxolitinib is a JAK 1/2 inhibitor that can decrease spleen size, relieve constitutional symptoms, reduce transfusion requirement and prolongs survival in some patients. Uncommon adverse reaction of Ruxolitinib includes reactivation of tuberculosis infection.
Methods
We are describing 4 patients of myelofibrosis who have had reactivation of tuberculosis, whilst on Ruxolitinib. Data was collected retrospectively. Patients were followed up actively during antituberculous treatment
Results
Age (yr) sex Diagnosis JAK2 CALR Ruxolitinib initi TB reactivation Site of reactivation ATT outcome
53 F SMF/PV + - Dec, 2013 15 months Abdominal 6 month Alive
33 F PMF + - Feb, 2016 14 months Pulmonary 6 months Alive 40 M PMF - + Apr, 2017 4 months Lymphnode 6 months Alive 54 M PMF + - Mar, 2017 11 months Pulmonary 6 months Alive
Conclusion
Tuberculosis infection was observed in 4 patients who were being treated with Ruxolitinib. This case series highlights the importance of screening for latent tuberculosis in patients from highly endemic areas before commencing on Ruxolitinib.
Keyword(s):